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Edited by Lukas HuberAbstract The involvement of caspase-3 and its failure in the
induction of DNA fragmentation during erythropoiesis were
investigated with TF-1 cells. During erythroid diﬀerentiation,
caspase-3 activation and cleavage of caspase-3 substrates such
as ICAD (inhibitor of caspase-activated DNase) were detected
without concomitant phosphatidyl-serine (PS) externalization
and DNA fragmentation. These observations are in contrast to
our understanding that DNA is degraded by CAD (caspase-acti-
vated DNase) when ICAD is cleaved by caspase-3. Our study
demonstrates that CAD is downregulated at the mRNA and pro-
tein level during the erythroid diﬀerentiation in TF-1 cells. This
provides a mechanism for the ﬁrst time how cells avoid DNA
fragmentation with activated caspase-3.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a fundamental process of life. Execution of
apoptosis is controlled and regulated by a family of cysteine
proteases called caspases [1]. Apparently, erythropoiesis and
apoptosis seem like two opposing processes. However, they ap-
pear to share a common consequence of losing cell nucleus and
mitochondria, and the activation of caspase-3 [2–6]. For the
erythroid development, caspase-3 activation is required. Intro-
duction of inhibitor or small interfering RNA against caspase-
3 into early erythroid cells impaired their maturation [2,7]. On
the other hand, caspase-3 activation was able to trigger apop-
tosis in erythroid cells by the deprivation of erythropoietin
(EPO) [8–10]. Therefore, to understand how caspase-3 is atten-
tively regulated during erythropoiesis is important. For thisAbbreviations: CAD, caspase-activated DNase; EPO, erythropoietin;
GPA, glycophorin A; GADPH, glyceraldehyde-3-phosphate dehydro-
genase; GM-CSF, granulocyte-macrophage colony stimulating factor;
Hb, hemoglobin; ICAD, inhibitor of the caspase-activated DNase;
MAb, monoclonal antibody; PARP, poly (ADP-ribose) polymerase;
PI, propidium iodide; PS, phosphatidylserine; STS, staurosporine;
TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling
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investigate whether caspase-3 is activated during the process
of erythropoiesis and to elucidate the mechanism through
which erythroid cells bypass the cell death program. TF-1 is
a human cell line which shows many characteristics of ery-
throid cells. They can be induced to diﬀerentiate into more ma-
ture erythroid cells when cultured with EPO [11–13]. In our
study, we demonstrated that caspase-3 was activated in TF-1
cells during erythroid diﬀerentiation. However, such changes
did not necessarily induce signs of apoptosis. Results from
our study show a novel mechanism that, during erythropoiesis,
a cell can avoid DNA fragmentation with activated caspase-3
by downregulating caspase-activated DNase (CAD) at the
mRNA and protein level.2. Materials and methods
2.1. Chemicals and reagents
Recombinant human EPO and granulocyte-macrophage colony
stimulating factor (GM-CSF) were, respectively, purchased from
Roche and Sigma. Caspase-3 inhibitor z-DQMD-ﬂuoromethylketone
(FMK) was obtained from Calbiochem.
2.2. Cell culture and diﬀerentiation induction
Human cell line TF-1 was purchased from American Type Culture
Collection (ATCC). Cells were maintained at 37 C, 5% CO2 in RPMI
1640 medium (Gibco) supplemented with 10% (v/v) fetal bovine serum
(FSC), 1% (v/v) penicillin–streptomycin, 1 mM sodium pyruvate, 4.5 g/l
glucose (Gibco) and 2 ng/ml GM-CSF, according to the ATCC instruc-
tions. Prior to induction of diﬀerentiation, cells were kept in a medium
with FCS overnight, followed by the addition of EPO (1 U/ml) on the
next day. Renewal of medium and EPO (1 U/ml) were done on alterna-
tive days and the cell density was maintained at 4 · 105 cells/ml.
2.3. Assays for cell diﬀerentiation
Cell diﬀerentiation was evaluated by cell surface marker and hemo-
globin (Hb) content. For glycophorin A (GPA) staining, cells were
analyzed using ﬂow cytometry (Becton Dickinson, FacSort) with phy-
coerythrin (PE)-conjugated mouse anti-GPA monoclonal antibody
(MAb) (Pharmingen). The Hb content was estimated by staining cells
with benzidine (0.4% w/v), the % of benzidine-positive cells with blue in
color was assessed under light microscope and cell were counted from
three diﬀerent ﬁelds, each consisted of at least 200 cells.
2.4. Caspase-3 activity assay
Cells were incubated with ﬂuorogenic caspase-3 inhibitor FAM-
DEVD-FMK (Apologix) according to manufacturer’s instruction.
Brieﬂy, 0.3 ml of cells (1 · 106/ml) were stained in dark with 10 ll of
30· working solution containing FAM-DEVD-FMK for 1 h at
37 C and 5% CO2. The cells were then analyzed by ﬂow cytometry
after washing.blished by Elsevier B.V. All rights reserved.
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Apoptosis was determined using annexin-V/PI (propidium iodide)
method. 1 · 106 cells were resuspended with 100 ll HEPES buﬀer con-
tained 2% (v/v) annexin-V–FITC for 20 min at room temperature, and
then with 400 ll HEPES buﬀer contained PI (2.5 lg/ml) for another
20 min before ﬂow cytometric analysis. For one single analysis, the
ﬂuorescence properties of 10000 cells within gates were collected. Posi-
tioning of quadrants on annexin-V/PI plots was performed to distin-
guish living cells (annexin-V/PI), early apoptotic cells (annexin-V+/
PI), late apoptotic cells (annexin-V+/PI+) by using digitonin (2 mg/
ml) to identify annexin-V+/PI+ cells.
2.6. Detection of DNA fragmentation
DNA fragmentation was investigated by In Situ Cell DeathDetection
kit (Roche) using terminal deoxynucleotide transferase (TdT)-mediated
dUTP nick-end labeling (TUNEL) technique. Brieﬂy, 2 · 106 cells were
washed with PBS and ﬁxed with 2% paraformaldehyde for 1 h, followed
by permeabilization with 0.1%TritonX-100 and 0.1% sodium citrate on
ice for 2 min. Thereafter, cells were incubated in a mixture of TdT and
ﬂuorescein-incorporated nucleotides at 37 C for 1 h, and the labeled
cells were then examined by ﬂow cytometry.
2.7. Western blotting
Cells were lysed in 1% (w/v) SDS, 1 mMNa3VO4, 10 mMTris, 5 mM
MgCl2 with protease inhibitors 21 lg/ml aprotinin, 5 lg/ml leupeptin
and 1 mM PMSF at pH 7.4 for 1 h at room temperature. Samples were
then boiled for 10 min and then centrifuged at 14000 rpm at 4 C. Sub-
sequently, 25 lg of protein extracts were analyzed by 12% SDS–PAGE
and blotted to PVDF (polyvinylidene ﬂuoride) membrane. Membranes
were incubated with mouse anti-human caspase-3 MAb (for pro-cas-
pase-3) (Santa Cruz), rabbit polyclonal anti-caspase-3 Ab (for active
form) (Santa Cruz), rabbit polyclonal anti-ICAD Ab (Santa Cruz),
mouse anti-CAD MAb (Santa Cruz), rat anti-GATA-1 MAb (Santa
Cruz), rabbit polyclonal anti-PARP Ab (Santa Cruz), mouse anti-Bcl-
XL MAb (Zymed) or mouse anti-human b-tubulin MAb (Boehringer)
followed by horseradish peroxidase-conjugated secondary Ab (Santa
Cruz) and developed with ECL reagent (Amersham).
2.8. Real-time PCR
To assess the relative expression of CAD transcripts during TF-1 dif-
ferentiation, RNA was extracted from EPO-treated or untreated TF-1
cells using trizol reagent (Sigma) andﬁrst-strand cDNAsynthesizedwith
ThermoScript RT-PCR kit (Invitrogen), which was used as templates
for real time PCR.Quantitative real timePCRwas performed by anABI
Prism 7700 sequence detection system (Applied Biosystems) using Taq-
Man Gene Expression assays [Assay IDs for diﬀerent genes: CAD:
Hs00237077 m1; ICAD: Hs00189336 m1;GAPDH: Hs99999905 m1].
Ampliﬁcations were performed at 95 C for 10 min and ampliﬁed for
40 cycles of 15 s at 95 C and 60 s at 60 C. Relative amount of CAD
and inhibitor of the caspase-activated DNase (ICAD) from diﬀerent
samples were both normalized with glyceraldehyde-3-phosphate dehy-
drogenase (GADPH) according to manufacturer’s protocol.3. Results
3.1. Caspase activation is involved in erythropoiesis
TF-1 is a commonly used model for the study of human ery-
throid diﬀerentiation [11–13]. After EPO treatment, TF-1 cells
produced Hb (Suppl. Fig. 1a), expressed erythroid-speciﬁc
transcription factors TAL-1 and GATA-1, and increased the
amount of Bcl-XL (Suppl. Fig. 1b). According to the erythroid
markers expression proﬁle (Hb, TAL-1, GATA-1, Bcl-XL and
glycophorin A (GPA) (see later)) proposed by Koury et al.
[14], TF-1 cells became the polychromatophilic–orthochro-
matic normoblasts after 12 days of EPO treatment. These
observations indicate that TF-1 is a useful model for the study
of erythropoiesis.
Activation of caspase-3 in TF-1 cells after EPO treatment
was determined by using ﬂow cytometry with PE-conjugatedanti-GPA MAb and FAM-DEVD-FMK. GPA is a marker ex-
pressed throughout the erythroid diﬀerentiation process while
FAM-DEVD-FMK is a ﬂuorogenic inhibitor of caspase-3 and
related caspases which produces green ﬂuorescence when binds
to the active caspases [15]. As can be seen in Fig. 1, only 2% of
cells were found in the two right quadrants for caspase-3 activ-
ity in the untreated group suggesting that no caspase-3 activity
was detected in the control. On the other hand, more than 30%
of the cells treated with a potent apoptosis inducer
staurosporine (STS) showed caspase-3 activity. However, no
signiﬁcant increase in the GPA level was detected in the
STS-treated cells suggesting that GPA expression is not a con-
comitant event with the activation of caspase-3. In the EPO-
treated cells, the % of cells with simultaneous caspase-3 activity
and GPA expression increased in a time-dependent manner
from 2.3% at day 2 to 30.6% at day 8 (upper right quadrants,
Fig. 1). It is noteworthy that the expression of GPA started
earlier than the activation of caspase-3. Also, most of the acti-
vated caspase-3 signals were found in the GPA+ cells in the la-
ter phase of development further indicating that activation of
caspase-3 is associated with erythroid diﬀerentiation.
In the Western blot analysis (Fig. 2), it is clear that the p17
active form of caspase-3 was not detected during the ﬁrst 4
days of EPO treatment. However, the p17 caspase-3 was ob-
served from day 6 to day 12 with a concomitant decrease in
pro-caspase-3. At the same time, poly (ADP-ribose) polymer-
ase (PARP) (116 kDa), a caspase-3 speciﬁc substrate for
DNA repair [16], was cleaved and its cleaved form
(85 kDa) was found from day 6 to day 12 after EPO treat-
ment. Diﬀerent from the ﬂow cytometric analysis in Fig. 1,
caspase-3 activity was undetectable in Fig. 2 at day 4. This
discrepancy could be explained by the fact that FAM-
DEVD-FMK is able to detect both caspase-3 and -7. In fact,
it has been shown in developing erythroblasts that erythroid-
speciﬁc transcription factor TAL-1 is cleaved by caspase-7
[17].
To further establish the role of caspase-3 in the erythroid dif-
ferentiation, we incubated the EPO-treated cells with a cas-
pase-3 speciﬁc inhibitor z-DQMD-FMK [18]. As shown in
Fig. 3A (left panel), GPA expression increased steadily in a
time-dependent manner in the absence of inhibitor. When
the EPO-treated cells were incubated with z-DQMD-FMK
(100 lM) for the last 48 h (not for 6 or 8 days), cells from
the day 8 and day 6 treatments displayed a relatively lower le-
vel of GPA when compared to their corresponding controls
(49.5% vs. 35.0% at day 8, and 39.7% vs. 32.2% at day 6).
However, no signiﬁcant attenuation was observed before the
day 4 culture (Fig. 3A, right panel and Fig. 3B). Therefore,
it seems likely that z-DQMD-FMK could not block the
GPA expression in the early phase (days 0–4) but reduced dif-
ferentiation, at least in part, in the later stage of erythroid dif-
ferentiation after EPO treatment. These results correlate well
with our earlier observations that caspase-3 was activated in
the day 6 culture. Also, these ﬁndings are in agreement with
other observations that caspase activation is required for
erythroblast maturation [4].
3.2. Signs of apoptosis are not found during erythroid
diﬀerentiation
Because of the activation of caspase-3, it is of interest to
examine whether signs of apoptosis such as phosphatidylserine
(PS) externalization, loss of membrane integrity, and DNA
Fig. 1. Activation of caspase-3 in TF-1 cells during erythropoiesis. TF-1 cells (4 · 105/ml) were cultured with EPO (1 U/ml) for diﬀerent days or with
staurosporine (STS) (0.5 lM) for 24 h at 37 C, 5% CO2. Erythroid marker GPA and caspase-3 activity were determined simultaneously by anti-GPA
MAb and FAM-DEVD-FMK with ﬂow cytometry. Figures at the corners represent the % of cells in the corresponding quadrants.
Fig. 2. Change of caspase-3, PARP, ICAD and CAD in TF-1 cells
after EPO treatment. TF-1 cells (4 · 105/ml) were cultured with EPO
(1 U/ml) for diﬀerent days at 37 C, 5% CO2. After cell lysis, lysates
containing equal amount of proteins per lane were subject to standard
SDS–PAGE and Western analysis with antibodies for the pro-caspase-
3 (35 kDa), active caspase-3 (17 kDa), PARP (116 kDa), cleaved
PARP (85 kDa), ICAD (45 kDa), CAD (40 kDa) and b-tubulin
(55 kDa, as an internal control).
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the standard annexin-V/PI assay (Fig. 4), STS increased the %
of the early apoptotic cells (annexin-V+/PI) from 3.3% (con-
trol) to 21.1% of the total population in a 24 h-treatment.
However, no signiﬁcant change was observed in the early (an-
nexin-V+/PI) and late apoptotic (annexin-V+/PI+) cells in the
EPO-treated or control group suggesting that apoptosis was
not found in the EPO-treated cells. Similar observations were
found in the TUNEL assays for DNA fragmentation in the
EPO-treated groups (<3.2% are TUNEL-positive, Fig. 5A, leftpanel). However, when cells were treated with STS for the last
24 h in the experiments, DNA fragmentation was obtained in
the EPO-untreated group (32.4% vs. 2.1%, Fig. 5A, right pa-
nel). Interestingly, a reduction in DNA fragmentation was evi-
dent in the diﬀerentiating cells after STS treatment (Fig. 5A,
right panel). The % of cells with DNA cleavage dropped from
32.4% at day 0 to 11% at day 8 after EPO treatment. The long-
er the incubation time with EPO, the less the DNA fragmenta-
tion was elicited by STS (Fig. 5B). Based on these ﬁndings, it
can be concluded that protective mechanisms might have
emerged to antagonize the apoptotic eﬀect of caspase-3 to
avoid DNA fragmentation when TF-1 diﬀerentiates along
the erythroid pathway.
3.3. EPO induced cleavage of ICAD and downregulation of
CAD
In the ﬁnal execution phase of apoptosis, caspases induce
DNA fragmentation through the activation of CAD [19,20].
In growing cells, CAD remains inactive and forms an inactive
cytoplasmic heterodimer with ICAD [21]. During apoptosis,
caspase-3 cleaves ICAD and releases ICAD from CAD.
CAD then forms an active homodimeric endonuclease in the
nucleus for DNA fragmentation [22]. To determine whether
ICAD was cut by caspase-3 during diﬀerentiation, Western
blot analysis was performed. To our surprise, ICAD, also a
caspase-3 substrate [23], was cleaved in the EPO-treated cells
(Fig. 2). These observations prompted us to investigate
whether a change in CAD level occurred in the diﬀerentiated
TF-1 cells. Interestingly, CAD protein started to disappear
from day 4 after EPO treatment (Fig. 2). Similar observation
Fig. 3. Caspase-3 inhibitor blocks the expression of GPA in the EPO-treated TF-1 cells. TF-1 cells (4 · 105/ml) were treated with EPO (1 U/ml) for
diﬀerent days in the presence or absence of a caspase-3 speciﬁc inhibitor z-DQMD-FMK (100 lM) at 37 C, 5% CO2 for the last two days.
Expression of GPA was then determined by ﬂow cytometry. Figure in each determination represents the % of cells expressing GPA in the selected
region (A). The experiment is repeated for three times and statistically analyzed (right panel), means ± S.E.M., n = 3, #P < 0.05, ##P < 0.001,
*P > 0.05 (B).
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body (Calbiochem) (data not shown). To further explore the
nature of this decrease, CAD and ICAD mRNA in TF-1 cellsFig. 4. Eﬀect of EPO on the induction of apoptosis. TF-1 cells
(4 · 105/ml) were treated with medium alone, medium with EPO (1 U/
ml) for 4 days or 8 days, or staurosporine (STS) (0.5 lM), for 24 h at
37 C, 5% CO2. After treatment, cells were incubated with FITC
labeled annexin-V and PI. After washing, cells were submitted to ﬂow
cytometric analysis. Numbers in the panels represent the % of cells
found in the corresponding quadrant.after EPO treatment were extracted and their level were mea-
sured by real time PCR. As illustrated in Fig. 6, the ratio of
CAD mRNA to glyceraldehyde-3-phosphate dehydrogenase
mRNA decreased from 1.2 at day 2 to 0.4 at day 4 after nor-
malization. Such low mRNA level of CAD was kept until day
12 of treatment. On the other hand, the mRNA level of ICAD
did not show signiﬁcant change during the EPO treatments
(Fig. 6). These observations therefore indicate a protective
mechanism developed at the CAD level in the TF-1 cells dur-
ing erythroid diﬀerentiation, which explains for the ﬁrst time
how a cell avoids DNA fragmentation with activated caspases
during erythropoiesis.4. Discussion
Although caspases are the executioners of apoptosis, grow-
ing evidence indicates that they also play non-apoptotic func-
tions in diﬀerent cell types [2–6]. In our model, caspase-3 was
found to be activated in TF-1 cells during erythroid diﬀerenti-
ation between day 6 to day 12 after EPO treatment with con-
comitant cleavages of caspase-3 substrates such as PARP and
ICAD (Figs. 1 and 2).
Until now, the role of caspase-3 in erythropoiesis remains
controversial. For instance, no obvious defect in erythropoiesis
was observed in caspase-3/ knock-out mice [24]. On the con-
trary, the use of siRNA and inhibitor against caspase-3 atten-
uated the erythroid cells maturation [2,4]. In our study,
caspase-3 activity was detected in the GPA+ cells after EPO
treatment. These ﬁndings in Fig. 1 ruled out the possibility that
the caspase-3 activity was generated by the EPO-unresponsive
cells. When TF-1 cells were incubated with caspase-3 inhibitor
Fig. 5. EPO did not induce DNA fragmentation in TF-1 cells. TF-1 cells (4 · 105/ml) were treated with EPO (1 U/ml) for diﬀerent days in the
presence or absence of staurosporine (STS) (1 lM, for the last 24 h) at 37 C, 5% CO2. DNA fragmentation was then determined by TUNEL assays.
Figure in each panel represents the percentage of cells with DNA fragmentation in the M1 region (A). The experiment is repeated for three times and
statistically analyzed, means ± S.E.M., n = 3, ##P < 0.001 (B).
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(Fig. 3) and CD71 (data not shown) were suppressed.
These suggest that caspase-3 activation is associated with
and required, at least in part, for the process of erythroid
development.One interesting point in our system is that neither PS exter-
nalization nor DNA fragmentation was observed throughout
the erythroid diﬀerentiation process (Figs. 4 and 5). These ﬁnd-
ings therefore indicate that caspase-3 activity in the developing
erythroid cells did not trigger apoptosis. Also, the ability of the
EPO-treated cells to undergo apoptosis appeared to be dwin-
dled, as shown by the diminutive DNA cleavage upon STS
treatment (Fig. 5). These ﬁndings suggest that the EPO-treated
cells are protected from apoptosis. One of the models to ex-
plain this is the selective cleavage of caspase substrates. Exam-
ple along this line is ICAD that remained unchanged during
erythropoiesis as a result of a transient caspase-3 activation
[4]. If this is the only mechanism, when we applied STS to
the cells, a full activity of caspase-3 would have activated
CAD, and DNA fragmentation would have been obtained.
Yet, we observed a protection against DNA fragmentation
and cleavage of ICAD in the EPO-treated cells (Fig. 2). With
these puzzling results, we examined the change in CAD. Inter-
estingly, we found a down-regulation of CAD at the protein
(Fig. 2) and mRNA (Fig. 6) level starting from day 4 of the
EPO treatment. From the same preparations, no such change
was observed in the ICAD mRNA (Fig. 6). Therefore, our
ﬁndings illustrate a treatment on CAD for caspase-3 to per-
form its non-apoptotic functions. Also, this observation ex-
plained why no protection against DNA fragmentation was
obtained in the EPO-treated groups before day 4 (Fig. 5). At
the moment, there are many questions remained to be an-
swered. For example, what triggers the down-regulation of
1970 J.C.-K. Lui, S.-K. Kong / FEBS Letters 580 (2006) 1965–1970CAD and activation of caspase-3; what are the substrates for
the active caspase-3 during erythropoiesis. More work is
needed to elucidate how caspase-3 modulates erythropoiesis.Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.febslet.2006.02.059.References
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